Published in Proc Natl Acad Sci U S A on May 23, 2000
Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation. Proc Natl Acad Sci U S A (2002) 3.56
Rapid end-point quantitation of prion seeding activity with sensitivity comparable to bioassays. PLoS Pathog (2010) 2.63
Evidence of a molecular barrier limiting susceptibility of humans, cattle and sheep to chronic wasting disease. EMBO J (2000) 2.42
Ex vivo propagation of infectious sheep scrapie agent in heterologous epithelial cells expressing ovine prion protein. Proc Natl Acad Sci U S A (2001) 2.16
Conversion of raft associated prion protein to the protease-resistant state requires insertion of PrP-res (PrP(Sc)) into contiguous membranes. EMBO J (2002) 2.16
Sulfated glycans and elevated temperature stimulate PrP(Sc)-dependent cell-free formation of protease-resistant prion protein. EMBO J (2001) 1.95
Human variant Creutzfeldt-Jakob disease and sheep scrapie PrP(res) detection using seeded conversion of recombinant prion protein. Protein Eng Des Sel (2009) 1.49
The strain-encoded relationship between PrP replication, stability and processing in neurons is predictive of the incubation period of disease. PLoS Pathog (2011) 1.49
A molecular switch controls interspecies prion disease transmission in mice. J Clin Invest (2010) 1.41
Changing a single amino acid in the N-terminus of murine PrP alters TSE incubation time across three species barriers. EMBO J (2001) 1.30
Parallel in-register intermolecular β-sheet architectures for prion-seeded prion protein (PrP) amyloids. J Biol Chem (2014) 1.27
Trans-dominant inhibition of prion propagation in vitro is not mediated by an accessory cofactor. PLoS Pathog (2009) 1.21
Glycosylation influences cross-species formation of protease-resistant prion protein. EMBO J (2001) 1.17
Prion species barrier between the closely related yeast proteins is detected despite coaggregation. Proc Natl Acad Sci U S A (2007) 1.17
Prion strain-dependent differences in conversion of mutant prion proteins in cell culture. J Virol (2006) 1.14
Pregnancy status and fetal prion genetics determine PrPSc accumulation in placentomes of scrapie-infected sheep. Proc Natl Acad Sci U S A (2002) 1.07
Dissociation of infectivity from seeding ability in prions with alternate docking mechanism. PLoS Pathog (2011) 1.07
Octapeptide repeat insertions increase the rate of protease-resistant prion protein formation. Protein Sci (2006) 1.07
PRNP variation in UK sporadic and variant Creutzfeldt Jakob disease highlights genetic risk factors and a novel non-synonymous polymorphism. BMC Med Genet (2009) 1.06
Methionine sulfoxides on prion protein Helix-3 switch on the alpha-fold destabilization required for conversion. PLoS One (2009) 1.01
Efficient conversion of normal prion protein (PrP) by abnormal hamster PrP is determined by homology at amino acid residue 155. J Virol (2001) 1.00
A role for intermolecular disulfide bonds in prion diseases? Proc Natl Acad Sci U S A (2001) 0.99
Deletion of beta-strand and alpha-helix secondary structure in normal prion protein inhibits formation of its protease-resistant isoform. J Virol (2001) 0.98
Preclinical detection of variant CJD and BSE prions in blood. PLoS Pathog (2014) 0.97
Identifying key components of the PrPC-PrPSc replicative interface. J Biol Chem (2008) 0.91
Theoretical modeling of prion disease incubation. Biophys J (2003) 0.91
Heterologous cross-seeding mimics cross-species prion conversion in a yeast model. BMC Biol (2009) 0.89
Critical significance of the region between Helix 1 and 2 for efficient dominant-negative inhibition by conversion-incompetent prion protein. PLoS Pathog (2013) 0.89
Prion propagation: the role of protein dynamics. Prion (2007) 0.83
Recombinant human prion protein inhibits prion propagation in vitro. Sci Rep (2013) 0.82
Prion propagation in vitro: are we there yet? Int J Med Sci (2008) 0.82
Orthogonal cross-seeding: an approach to explore protein aggregates in living cells. Biochemistry (2008) 0.82
Heterozygous inhibition in prion infection: the stone fence model. Prion (2009) 0.82
Enhanced virulence of sheep-passaged bovine spongiform encephalopathy agent is revealed by decreased polymorphism barriers in prion protein conversion studies. J Virol (2013) 0.82
Mouse prion protein (PrP) segment 100 to 104 regulates conversion of PrP(C) to PrP(Sc) in prion-infected neuroblastoma cells. J Virol (2012) 0.80
Treatment of Prion Disease with Heterologous Prion Proteins. PLoS One (2015) 0.78
Early and Non-Invasive Detection of Chronic Wasting Disease Prions in Elk Feces by Real-Time Quaking Induced Conversion. PLoS One (2016) 0.78
Dynamic interactions of Sup35p and PrP prion protein domains modulate aggregate nucleation and seeding. Prion (2009) 0.76
How do amino acid substitutions affect the amyloidogenic properties and seeding efficiency of prion peptides. Amino Acids (2013) 0.76
Strain conformation controls the specificity of cross-species prion transmission in the yeast model. Prion (2016) 0.75
Insights into prion biology: integrating a protein misfolding pathway with its cellular environment. Prion (2011) 0.75
Potential approaches for heterologous prion protein treatment of prion diseases. Prion (2016) 0.75
A Medicinal Herb Scutellaria lateriflora Inhibits PrP Replication in vitro and Delays the Onset of Prion Disease in Mice. Front Psychiatry (2012) 0.75
Prion protein scrapie and the normal cellular prion protein. Prion (2016) 0.75
Assessing proteinase K resistance of fish prion proteins in a scrapie-infected mouse neuroblastoma cell line. Viruses (2014) 0.75
Prions. Proc Natl Acad Sci U S A (1998) 27.80
Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature (1997) 15.73
The same prion strain causes vCJD and BSE. Nature (1997) 12.49
Mice devoid of PrP are resistant to scrapie. Cell (1993) 11.46
Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins. J Virol (1987) 7.05
Transgenetic studies implicate interactions between homologous PrP isoforms in scrapie prion replication. Cell (1990) 6.17
Cell-free formation of protease-resistant prion protein. Nature (1994) 6.07
Secondary structure analysis of the scrapie-associated protein PrP 27-30 in water by infrared spectroscopy. Biochemistry (1991) 5.53
The scrapie-associated form of PrP is made from a cell surface precursor that is both protease- and phospholipase-sensitive. J Biol Chem (1991) 4.23
Non-genetic propagation of strain-specific properties of scrapie prion protein. Nature (1995) 4.22
N-terminal truncation of the scrapie-associated form of PrP by lysosomal protease(s): implications regarding the site of conversion of PrP to the protease-resistant state. J Virol (1991) 3.55
Scrapie and cellular prion proteins differ in their kinetics of synthesis and topology in cultured cells. J Cell Biol (1990) 3.46
Propagation of prions with artificial properties in transgenic mice expressing chimeric PrP genes. Cell (1993) 2.93
Molecular assessment of the potential transmissibilities of BSE and scrapie to humans. Nature (1997) 2.80
Chimeric prion protein expression in cultured cells and transgenic mice. Protein Sci (1992) 2.67
The genomic identity of different strains of mouse scrapie is expressed in hamsters and preserved on reisolation in mice. J Gen Virol (1989) 2.64
Species specificity in the cell-free conversion of prion protein to protease-resistant forms: a model for the scrapie species barrier. Proc Natl Acad Sci U S A (1995) 2.58
Control of actin assembly and disassembly at filament ends. Curr Opin Cell Biol (2000) 2.44
Prion protein and the transmissible spongiform encephalopathies. Trends Cell Biol (1997) 2.39
Evidence that the transmission of one source of scrapie agent to hamsters involves separation of agent strains from a mixture. J Gen Virol (1978) 2.33
Scrapie infectivity found in resistant species. Nature (1998) 2.28
Entry versus blockade of brain infection following oral or intraperitoneal scrapie administration: role of prion protein expression in peripheral nerves and spleen. J Virol (2000) 1.93
A single hamster PrP amino acid blocks conversion to protease-resistant PrP in scrapie-infected mouse neuroblastoma cells. J Virol (1995) 1.87
Prion protein NMR structure and species barrier for prion diseases. Proc Natl Acad Sci U S A (1997) 1.86
Heterologous PrP molecules interfere with accumulation of protease-resistant PrP in scrapie-infected murine neuroblastoma cells. J Virol (1994) 1.85
Chaperone-supervised conversion of prion protein to its protease-resistant form. Proc Natl Acad Sci U S A (1997) 1.79
Aggregates of scrapie-associated prion protein induce the cell-free conversion of protease-sensitive prion protein to the protease-resistant state. Chem Biol (1995) 1.68
Specific binding of normal prion protein to the scrapie form via a localized domain initiates its conversion to the protease-resistant state. EMBO J (1999) 1.64
Scrapie infectivity correlates with converting activity, protease resistance, and aggregation of scrapie-associated prion protein in guanidine denaturation studies. J Virol (1997) 1.38
Molecular genetics of transmissible spongiform encephalopathies. J Biol Chem (1999) 1.36
Modification of a strain of mouse-adapted scrapie by passage through rats. Res Vet Sci (1968) 1.22
Species-independent inhibition of abnormal prion protein (PrP) formation by a peptide containing a conserved PrP sequence. J Virol (1999) 1.16
Characterization of scrapie agent isolated from sheep in Japan. Microbiol Immunol (1985) 1.11
Letter: Interspecies transmission of scrapie-like diseases. Lancet (1975) 0.79
Cell-free formation of protease-resistant prion protein. Nature (1994) 6.07
Non-genetic propagation of strain-specific properties of scrapie prion protein. Nature (1995) 4.22
Molecular assessment of the potential transmissibilities of BSE and scrapie to humans. Nature (1997) 2.80
Species specificity in the cell-free conversion of prion protein to protease-resistant forms: a model for the scrapie species barrier. Proc Natl Acad Sci U S A (1995) 2.58
Evidence of a molecular barrier limiting susceptibility of humans, cattle and sheep to chronic wasting disease. EMBO J (2000) 2.42
Prion protein and the transmissible spongiform encephalopathies. Trends Cell Biol (1997) 2.39
Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol (2000) 2.15
Production of monoclonal antibodies reactive with a denatured form of the Friend murine leukemia virus gp70 envelope protein: use in a focal infectivity assay, immunohistochemical studies, electron microscopy and western blotting. J Virol Methods (1991) 2.01
Sulfated glycans and elevated temperature stimulate PrP(Sc)-dependent cell-free formation of protease-resistant prion protein. EMBO J (2001) 1.95
Analyses of frequency of infection, specific infectivity, and prion protein biosynthesis in scrapie-infected neuroblastoma cell clones. J Virol (1988) 1.92
Heterologous PrP molecules interfere with accumulation of protease-resistant PrP in scrapie-infected murine neuroblastoma cells. J Virol (1994) 1.85
The 100-kDa neurotensin receptor is gp95/sortilin, a non-G-protein-coupled receptor. J Biol Chem (1998) 1.84
Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines. Proc Natl Acad Sci U S A (1998) 1.80
Chaperone-supervised conversion of prion protein to its protease-resistant form. Proc Natl Acad Sci U S A (1997) 1.79
The chemistry of scrapie infection: implications of the 'ice 9' metaphor. Chem Biol (1995) 1.76
Neuron-specific expression of a hamster prion protein minigene in transgenic mice induces susceptibility to hamster scrapie agent. Neuron (1995) 1.71
Strains of [PSI(+)] are distinguished by their efficiencies of prion-mediated conformational conversion. EMBO J (2001) 1.70
Specific binding of normal prion protein to the scrapie form via a localized domain initiates its conversion to the protease-resistant state. EMBO J (1999) 1.64
Scrapie susceptibility-linked polymorphisms modulate the in vitro conversion of sheep prion protein to protease-resistant forms. Proc Natl Acad Sci U S A (1997) 1.54
The double life of the prion protein. Curr Biol (1996) 1.48
Partial unfolding and refolding of scrapie-associated prion protein: evidence for a critical 16-kDa C-terminal domain. Biochemistry (1996) 1.40
Astrocyte-specific expression of hamster prion protein (PrP) renders PrP knockout mice susceptible to hamster scrapie. EMBO J (1997) 1.36
Specific inhibition of in vitro formation of protease-resistant prion protein by synthetic peptides. J Biol Chem (1998) 1.35
Species-independent inhibition of abnormal prion protein (PrP) formation by a peptide containing a conserved PrP sequence. J Virol (1999) 1.16
A 60-kDa prion protein (PrP) with properties of both the normal and scrapie-associated forms of PrP. J Biol Chem (1995) 1.15
Species barriers in prion diseases--brief review. Arch Virol Suppl (2005) 1.14
N-terminal truncation of prion protein affects both formation and conformation of abnormal protease-resistant prion protein generated in vitro. J Biol Chem (2001) 1.12
Methods for studying prion protein (PrP) metabolism and the formation of protease-resistant PrP in cell culture and cell-free systems. An update. Mol Biotechnol (1999) 1.10
Structural aspects of Congo red as an inhibitor of protease-resistant prion protein formation. J Neurochem (1998) 1.09
Diagnostic implications of detection of proteinase K-resistant protein in spleen, lymph nodes, and brain of sheep. Am J Vet Res (1992) 1.07
Prion protein and the molecular features of transmissible spongiform encephalopathy agents. Curr Top Microbiol Immunol (2004) 1.04
Prion protein interconversions and the transmissible spongiform encephalopathies. Structure (1999) 1.02
Analysis of linkage between scrapie incubation period and the prion protein gene in mice. J Gen Virol (1990) 1.02
In vivo cytotoxicity of the prion protein fragment 106-126. J Biol Chem (2000) 1.02
The importance of the disulfide bond in prion protein conversion. Neuroreport (1998) 1.02
Foreign PrP expression and scrapie infection in tissue culture cell lines. Dev Biol Stand (1993) 1.01
Inhibition of interactions and interconversions of prion protein isoforms by peptide fragments from the C-terminal folded domain. J Biol Chem (2001) 1.01
Efficient conversion of normal prion protein (PrP) by abnormal hamster PrP is determined by homology at amino acid residue 155. J Virol (2001) 1.00
Protease sensitivity and nuclease resistance of the scrapie agent propagated in vitro in neuroblastoma cells. J Virol (1991) 1.00
Deletion of beta-strand and alpha-helix secondary structure in normal prion protein inhibits formation of its protease-resistant isoform. J Virol (2001) 0.98
Conformational change, aggregation and fibril formation induced by detergent treatments of cellular prion protein. J Neurochem (2001) 0.96
Growth of infective forms of Trypanosoma (T.) brucei on buffalo lung and Chinese hamster lung tissue culture cells. Acta Trop (1978) 0.95
Scrapie agent reflication without the prion protein? Curr Biol (1993) 0.94
Reversibility of scrapie-associated prion protein aggregation. J Biol Chem (2001) 0.94
In situ formation of protease-resistant prion protein in transmissible spongiform encephalopathy-infected brain slices. J Biol Chem (1997) 0.94
Inhibition of scrapie-associated PrP accumulation. Probing the role of glycosaminoglycans in amyloidogenesis. Mol Neurobiol (1995) 0.93
Purification of the neurotensin receptor from mouse brain by affinity chromatography. J Biol Chem (1989) 0.92
Secondary structure of the pentraxin female protein in water determined by infrared spectroscopy: effects of calcium and phosphorylcholine. Biochemistry (1992) 0.88
Prion protein and the scrapie agent: in vitro studies in infected neuroblastoma cells. Infect Agents Dis (1995) 0.87
[3H]SR 48692, the first nonpeptide neurotensin antagonist radioligand: characterization of binding properties and evidence for distinct agonist and antagonist binding domains on the rat neurotensin receptor. Mol Pharmacol (1995) 0.87
Novel therapeutic uses for porphyrins and phthalocyanines in the transmissible spongiform encephalopathies. Curr Opin Microbiol (1999) 0.86
Ontogenesis and binding properties of high-affinity neurotensin receptors in human brain. Brain Res (1992) 0.85
Solubilization and characterization of active neurotensin receptors from mouse brain. J Biol Chem (1988) 0.84
Inhibition of formation of protease-resistant prion protein by Trypan Blue, Sirius Red and other Congo Red analogs. Arch Virol Suppl (2000) 0.83
Internalization and intracellular mobilization of neurotensin in neuronal cells. Biochem Pharmacol (1994) 0.82
Antiaggregating antibody raised against human PrP 106-126 recognizes pathological and normal isoforms of the whole prion protein. Cell Mol Neurobiol (2001) 0.82
Metabolic pools of ATP in cultured bovine adrenal medullary chromaffin cells. J Neurochem (1986) 0.81
Equilibrium cation binding selectivity of the carboxylic ionophore narasin A: a comparison with transport selectivities reported in two biological test systems. Biochem Pharmacol (1986) 0.79
Stable expression of the mouse levocabastine-sensitive neurotensin receptor in HEK 293 cell line: binding properties, photoaffinity labeling, and internalization mechanism. Biochem Biophys Res Commun (1998) 0.79
Infrared analysis of ligand- and oxidation-induced conformational changes in hemoglobins and myoglobins. Arch Biochem Biophys (1995) 0.78
Analytical subcellular fractionation of rat pituitary homogenates with special reference to the subcellular localization and properties of alkaline phosphatases. Biochim Biophys Acta (1983) 0.78
Binding and internalization of iodinated neurotensin in neuronal cultures from embryonic mouse brain. Brain Res (1991) 0.78
Electron microscopic characterization of neonatal platelet ultrastructure: effects of sampling techniques. Thromb Res (1991) 0.77
Identification in the rat neurotensin receptor of amino-acid residues critical for the binding of neurotensin. Brain Res Mol Brain Res (1997) 0.77
Similar protein signatures for BSE and vCJD. Nat Med (1996) 0.77
Effects of reserpine and tetrabenazine on catecholamine and ATP storage in cultured bovine adrenal medullary chromaffin cells. J Neurochem (1987) 0.77
Growth of infective forms of Trypanosoma rhodesiense in vitro, the causative agent of African trypanosomiasis. Science (1978) 0.77
Measurement of altered aspartyl residues in the scrapie associated form of prion protein. Biochem Biophys Res Commun (1998) 0.76
The role of molecular conformation in ion capture by carboxylic ionophores: a circular dichroism study of narasin A in single-phase solvents and liposomes. Biochim Biophys Acta (1986) 0.76
Plasma Mitochondrial DNA Levels as a Biomarker of Lipodystrophy Among HIV-infected Patients Treated with Highly Active Antiretroviral Therapy (HAART). Curr Mol Med (2015) 0.75
Chromaffin vesicle function in intact cells. Ann N Y Acad Sci (1987) 0.75
Effects of bromocriptine on pituitary organelle marker enzyme activities in lactating and postlactating rats: selective activation of lysosomal prolactin proteolytic activity. Endocrinology (1984) 0.75
The solvent polarity dependent conformational equilibrium of the carboxylic ionophore narasin: a proton NMR study. Biochem Biophys Res Commun (1983) 0.75
Alteration of the endocannabinoid system in mouse brain during prion disease. Neuroscience (2010) 0.75
Internalization of neurotensin in cultured neurons. Ann N Y Acad Sci (1992) 0.75